MRD assessment of multiple myeloma patients who received carfilzomib by EuroFlow and a simple multicolor flow cytometry

MRD assessment of multiple myeloma patients who received carfilzomib by EuroFlow and a simple multicolor flow cytometry - MRD assessment of MM patients who received carfilzomib by EuroFlow and a simple MFC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027259

Enrollment

Registered

2017-05-15

Start date

2017-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Active multiple myeloma patients who were diagnosed by IMWG criteria and relapse/refractory after the treatments of bortezomib/lenalidomide/thalidomide and have achieved complete response (CR) post carfilzomib+lenalidomide+dexamethasone (KRD) therapy.

Exclusion criteria

Exclusion criteria: Dementia patients who can not understand this clinical research.

Design outcomes

Primary

Measure	Time frame
MRD correlation between a simple MFC (Kameda-Flow) and EuroFlow	—

Secondary

Measure	Time frame
(1) 1-year PFS and 3-year PFS post KRD treatment (2) 1-year OS and 3-year OS post KRD treatment (3) MRD negativity post KRD treatment	—

Countries

Japan

Contacts

Public ContactHiroyuki T akamatsu

Kanazawa University Hospital Hematology

takamaz@staff.kanazawa-u.ac.jp0762652276

Outcome results